Role of maintaining therapy in the treatment of malignant neoplasms
- 3 August 2023
- journal article
- research article
- Published by Media Sphere Publishing Group in P.A. Herzen Journal of Oncology
- Vol. 12 (4)
Abstract
The increase in the number and efficacy of antitumor therapy drugs is accompanied by the need for maintaining treatment. With an increase in the risk of adverse events, such as hepatotoxicity, hepatotropic drugs play a special role in the treatment of patients with malignant neoplasms. The presented clinical case demonstrates the efficiency of maintaining therapy with the drug Remaxol to reduce the frequency of adverse events when using brentuximab vedotin treatment regimens. Thus, the administration of remaxol at the initial stage of therapy can prevent the aggravation of clinical presentations and make it possible to continue the treatment using an effective antitumor regimen.Keywords
This publication has 8 references indexed in Scilit:
- Клинические рекомендации по коррекции гепатотоксичности, индуцированной противоопухолевой терапиейMalignant tumours, 2022
- Hodgkin lymphoma: A 2020 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2020
- Risk-adapted therapy for advanced-stage Hodgkin lymphomaHematology-American Society Hematology Education Program, 2018
- Safety Analysis of Brentuximab Vedotin from the Phase III AETHERA Trial in Hodgkin Lymphoma in the Post-Transplant Consolidation SettingTransplantation and Cellular Therapy, 2018
- REMAXOL: MECHANISMS OF ACTION AND APPLICATION IN REAL CLINICAL PRACTICEThe Russian Archives of Internal Medicine, 2016
- Succinate Receptors (SUCNR1) as a Potential Target for PharmacotherapyPharmaceutical Chemistry Journal, 2015
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- HIF-1α mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinomaJournal of Cell Science, 2003